Nonalcoholic fatty liver disease (Homo sapiens)

From WikiPathways

Revision as of 06:31, 16 October 2018 by AlexanderPico (Talk | contribs)
Jump to: navigation, search


Description

No description

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Dattaroy D, Pourhoseini S, Das S, Alhasson F, Seth RK, Nagarkatti M, Michelotti GA, Diehl AM, Chatterjee S; ''Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis.''; Am J Physiol Gastrointest Liver Physiol, 2015 PubMed Europe PMC Scholia
  2. Seki E, Brenner DA, Karin M; ''A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches.''; Gastroenterology, 2012 PubMed Europe PMC Scholia
  3. Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; ''Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.''; Cancer Lett, 2018 PubMed Europe PMC Scholia
  4. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L; ''Molecular mechanisms involved in NAFLD progression.''; J Mol Med (Berl), 2009 PubMed Europe PMC Scholia
  5. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ; ''Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.''; Gastroenterology, 2003 PubMed Europe PMC Scholia
  6. Larter CZ, Farrell GC; ''Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?''; J Hepatol, 2006 PubMed Europe PMC Scholia
  7. Armstrong LE, Guo GL; ''Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis.''; Curr Pharmacol Rep, 2017 PubMed Europe PMC Scholia
  8. Malhi H, Kaufman RJ; ''Endoplasmic reticulum stress in liver disease.''; J Hepatol, 2011 PubMed Europe PMC Scholia
  9. Farrell GC, van Rooyen D, Gan L, Chitturi S; ''NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.''; Gut Liver, 2012 PubMed Europe PMC Scholia
  10. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM; ''Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases.''; Free Radic Biol Med, 2008 PubMed Europe PMC Scholia
  11. Hotamisligil GS; ''Endoplasmic reticulum stress and the inflammatory basis of metabolic disease.''; Cell, 2010 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
135137view21:36, 6 August 2024EweitzRefine membrane layer
135136view21:32, 6 August 2024EweitzEconomize layout
134794view02:46, 27 July 2024EweitzRefine legend
134793view02:45, 27 July 2024EweitzStandardize case
123350view10:46, 17 July 2022EgonwMade multiple pathways clickable
98945view17:56, 16 October 2018AlexanderPicoOntology Term : 'liver disease pathway' added !
98944view17:55, 16 October 2018AlexanderPicoOntology Term : 'disease pathway' added !
98943view17:55, 16 October 2018AlexanderPicoOntology Term : 'nonalcoholic fatty liver disease' added !
98942view17:55, 16 October 2018AlexanderPicoOntology Term : 'hepatocyte' added !
98933view10:52, 16 October 2018EgonwReplaced a secondary ChEBI identifier.
98932view10:50, 16 October 2018EgonwRemoved funny chars in identifier.
98931view06:46, 16 October 2018AlexanderPicoModified description
98930view06:35, 16 October 2018AlexanderPicofixed paste characters in IDs
98929view06:31, 16 October 2018AlexanderPiconew pathway
98917view18:21, 15 October 2018AlexanderPicoNew pathway

External references

DataNodes

No datanodes

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP4396"
Personal tools